Original paper

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval

Volume: 101, Issue: 1, Pages: 131 - 137
Published: Oct 9, 2021
Abstract
The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world impact of ruxolitinib on OS in patients with MF. The US Medicare Fee-for-Service claims database (parts A/B/D) was used to identify patients with ≥ 1 inpatient or ≥ 2 outpatient claims with an MF...
Paper Details
Title
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
Published Date
Oct 9, 2021
Volume
101
Issue
1
Pages
131 - 137
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.